The Protein Expression Laboratory at the National Cancer Institute in Frederick, MD is seeking statements of capability or interest from parties interested in collaborative research to further develop a platform technology for the targeted intra-cellular delivery of proteins using virus-like particles (VLPs).
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks research and development partners or licensees for novel composite hydrogels that can be used in tissue repair and other applications. Single gel networks used in tissue engineering and tissue repair applications generally become softer and more flaccid as they swell. The gels described in this technology, however, which comprise a swellable crosslinked polymer hydrogel dispersed in a crosslinked polymer matrix, mimic critical material properties of tissue extracellular matrix (ECM), for instance, becoming stiffer and tougher upon swelling.
Scientists at the National Eye Institute (NEI) have developed an embryo culture chamber, which can be used to culture and image embryos. The chamber allows for the continuous imaging of the embryo for the culture period. NEI seeks research collaborations and/or licensees for the development of this culture and imaging chamber for murine embryos.
Researchers at the National Institute on Drug Abuse (NIDA) have developed an apparatus that is used to image rodents while they are awake. The biological effects of agents on the rats can be imaged (via MRI for instance) in real time over a prolonged period of time.
Researchers at the National Institute of Child Health and Human Development (NICHD) developed a device simulating a blast shock wave of the type produced by explosive devices such as bombs. The invention allows for the real-time study of blast effects on in vitro cell models. NICHD researchers seek licensing opportunities to further develop this device.
The National Cancer Institute (NCI) seeks licensees for an automated digital pathology device which integrates tissue sectioning, staining, and image acquisition. The device is compatible with high-throughput data analyses.
Researchers at the National Eye Institute (NEI), have developed a cryopreservation and cell recovery system designed specifically for the efficient cryopreservation, transportation and subsequent thawing of monolayers and tissues on a substrate. This closed cryopreservation/defrost system allows for sterility in addition to increased viability, recovery and safety of tissues that can be used for in vitro culture or surgical transplantation.
Researchers at the National Institutes of Health Clinical Center (NIHCC) and Northern Arizona University (NAU) seek licensing and/or co-development research collaborations for a wearable, pediatric, robotic exoskeleton that facilitates knee extension during walking to provide motorized movement assistance and training through the gait cycle. The Robotic Exoskeleton is specifically designed for therapy of crouch gait in children with cerebral palsy (CP). The design is a customizable human-machine interface that allows an individualized assistance protocol to help preserve and enhance muscle strength and control. Early clinical results from this intervention appear promising for a condition having few effective long-term interventions.
Engineered bacterial spores can provide many useful functions such as the treatment of infections, use as an adjuvant for the delivery of vaccines, and the enzymatic degradation of environmental pollutants. Researchers at the National Cancer Institute’s Laboratory of Molecular Biology have developed a novel, synthetic spore husk-encased lipid bilayer (SSHEL) particle that is uniquely suited for a variety of these functions. NCI seeks partners to license and/or co-develop this technology toward commercialization.
The National Cancer Institute's Laboratory of Pathology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize a method for target-activated microdissection.
The National Institute of Health - Clinical Center (NIH-CC) seeks licensing and/or co-development of a system and method for tracking eye movement to increase the efficacy of visual diagnoses by radiologists.
The National Cancer Institute (NCI) seeks research co-development opportunities and/or licensees for a new biomedical device for biopsy tissue collection and storage in a sterile, well-defined environment.
The National Institute on Aging's Cellular Biophysics Section is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize biological pacemakers.
Researchers in the National Cancer Institute’s Laboratory of Pathology have developed an improved tissue fixative solution that is formaldehyde-free. This novel fixative, BE70, significantly improves DNA, RNA, and protein biomolecule integrity in histological samples compared to traditional fixatives. Additionally, BE70 is compatible with current protocols and does not alter tissue processing. NCI seeks partners to license this technology.
Researchers at the National Cancer Institute (NCI) have developed an engineered storage unit for frozen tissue, that provides a permanent base on which to mount tissue frozen in OCT and an enclosure for storage. The unit provides for chain-of-custody labeling and acts as an insulating container to protect the specimen. Other elements include devices for freezing the tissue to the base, as well as a holder for the base to facilitate cryosectioning. Application of the storage system allows a frozen tissue specimen to be moved between storage and cryosectioning without loss of label, deformation of tissue, or thermal alterations.
Researchers at the National Eye Institute (NEI) developed a surgical tool to place tissue into position in the retina. The NEI seeks co-development or licensing to commercialize a prototype already in pre-manufacturing. Alternative uses will be considered.
Pre-clinical radiotracer biomedical research involves the use of compounds labeled with radioisotopes, including radio-ligand bio-distribution studies, cell binding studies, immune cell labeling techniques, and α-based therapies. Before this Micro-Dose Calibrator, measurement of pre-clinical level dosage for small animal studies was inaccurate and unreliable. This dose calibrator is a prototype ready for customer testing and scale-up. It is designed to accurately measure radioactive doses in the range of 50 nCi (1.8 kBq) to 100 µCi (3.7 MBq) with 99% precision. The NCI seeks co-development or licensing to commercialize it. Alternative uses will be considered.